Low-Dose Aminoglutethimide Plus Steroid Replacement in Advanced Breast Cancer Patients Resistant to Conventional Therapies
作者:
CrivellariDiana,
GalligioniEnzo,
FrustaciSergio,
GaspariniGiampietro,
VaccherEmanuela,
ReGiovanni Lo,
TalaminiRenato,
MonfardiniSilvio,
AmbrosoGiovanni,
期刊:
Cancer Investigation
(Taylor Available online 1989)
卷期:
Volume 7,
issue 2
页码: 113-116
ISSN:0735-7907
年代: 1989
DOI:10.3109/07357908909038277
出版商: Taylor&Francis
数据来源: Taylor
摘要:
AbstractIn an attempt to define the activity and toxicity of low-dose aminoglutethimide plus steroid replacement in advanced breast cancer, we treated 40 patients with aminoglutethimide 500 mg/day + hydrocortisone 50 mg/day. Previous treatment consisted of additive hormones in 29 patients, oophorectomy in 8, and chemotherapy in 32. Among the 37 patients evaluablefor response and toxicity, 5 objective responses (16.2%) and 20 stable diseases (54%) were noted. Toxicity, absent in 23 patients (62.I %) and mild in 14, consisted mainly of Grade I (WHO) nausea, drowsiness, cutaneous rash, and dizziness. Responders and patients with stable disease experienced a similar survival (median not reached at 22 months). Aminoglutethimide at low doses appears to be beneficial in patients refractory to conventional therapies even if the objective response rate is low.
点击下载:
PDF (333KB)
返 回